Financial Performance - The company's revenue for Q1 2023 was ¥156,494,544.37, representing a 10.38% increase compared to ¥141,779,121.55 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was ¥51,606,248.85, a 29.28% increase from ¥39,919,425.66 year-on-year[5] - The company reported a 34.31% increase in net profit after deducting non-recurring gains and losses, totaling ¥44,794,928.10 compared to ¥33,353,129.22 in the previous year[5] - Total operating revenue for Q1 2023 reached ¥156,494,544.37, an increase of 10.5% compared to ¥141,779,121.55 in the same period last year[21] - The operating profit for Q1 2023 was ¥60,230,108.07, an increase of 29.3% compared to ¥46,518,162.66 in the previous period[22] - The net profit for Q1 2023 reached ¥51,606,248.85, up 29.4% from ¥39,919,425.66 in the same period last year[22] - The total comprehensive income attributable to the parent company was ¥51,606,248.85, an increase from ¥39,919,425.66 in the previous year[22] Cash Flow and Investments - The net cash flow from operating activities reached ¥61,890,371.17, marking a significant increase of 175.78% compared to ¥22,441,786.64 in Q1 2022[5] - Cash flow from operating activities generated a net amount of ¥61,890,371.17, significantly higher than ¥22,441,786.64 in the previous year, marking an increase of 175.5%[24] - Total cash inflow from investment activities was ¥942,927,102.55, compared to ¥31,345,383.92 in the previous period, indicating a substantial increase[24] - The cash flow from investment activities resulted in a net outflow of ¥11,858,460.08, worsening from a net outflow of ¥3,171,032.05 in the previous year[24] - The cash and cash equivalents at the end of Q1 2023 totaled ¥308,972,576.39, down from ¥1,329,798,336.02 at the end of the previous period[24] Assets and Liabilities - The company's total assets as of March 31, 2023, were ¥2,134,702,585.08, up 1.73% from ¥2,098,360,763.12 at the end of the previous year[5] - Total liabilities decreased to ¥196,486,281.73 from ¥211,750,708.62, a reduction of 7.2%[20] - The company reported a decrease in short-term borrowings and a reduction in accounts payable, indicating improved liquidity management[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,558[11] - The largest shareholder, Suzhou Fushilai Technology Service Development Center, holds 60.22% of the shares, totaling 55,200,000 shares[11] - In Q1 2023, the company reported a total cash dividend distribution of RMB 53,168,600, which translates to RMB 5.80 per 10 shares for all shareholders[16] - The total number of shares for the dividend distribution is based on a total share capital of 91,670,000 shares[16] - The company has a total of 68,750,000 restricted shares, with 10,330,000 shares released during the period[15] - The largest unrestricted shareholder is Wujiang Dongfang Guofa Venture Capital Co., Ltd., holding 2,931,900 shares[12] - The company has a total of 55,200,000 restricted shares held by Suzhou Fushilai Technology Service Development Center, locked for 42 months[14] - The company’s shareholder Yang Chang holds 151,600 shares through a margin trading account[12] - The company’s major shareholders include Suzhou Guofa Angel Venture Capital with 1,758,800 shares and Suzhou Longju Chuanlian Venture Capital with 976,700 shares[12] - The company has a total of 350,000 shares held by shareholder Lu Jiangang, locked for 18 months[15] - The company’s shareholder Zhang Weidong holds 647,500 shares, with 1,375,000 shares released on March 29, 2023[15] - The company has a total of 300,000 shares held by shareholder Qian Yi, with 225,000 shares released during the period[15] Expenses and R&D - Total operating costs amounted to ¥105,348,284.97, up from ¥102,613,441.78, reflecting a rise of 2.1% year-over-year[21] - Research and development expenses for the quarter were ¥9,226,220.69, compared to ¥8,771,509.27 in the previous year, showing an increase of 5.2%[21] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[21] Other Financial Metrics - The weighted average return on equity decreased to 2.70% from 5.23% year-on-year[5] - Cash and cash equivalents rose to ¥308,972,576.39 from ¥259,687,908.54, representing a growth of 18.9%[19] - Inventory increased to ¥129,384,336.39 from ¥122,688,096.16, reflecting a rise of 5.5%[19] - The basic and diluted earnings per share for Q1 2023 were both ¥0.56, slightly down from ¥0.58 in the previous period[22] - The company did not report any income from asset disposals during the period[22]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year growth of 15%[12] - The net profit attributable to shareholders was 200 million RMB, an increase of 10% compared to the previous year[12] - The company's operating revenue for 2022 was ¥568,213,343.96, an increase of 8.92% compared to ¥521,695,665.95 in 2021[17] - The net profit attributable to shareholders for 2022 was ¥177,303,662.82, representing a significant increase of 47.51% from ¥120,201,415.72 in 2021[17] - The net profit after deducting non-recurring gains and losses was ¥172,416,638.82, up 49.39% from ¥115,415,204.48 in the previous year[17] - The total assets at the end of 2022 reached ¥2,098,360,763.12, a substantial increase of 116.26% from ¥970,306,076.54 at the end of 2021[17] - The net assets attributable to shareholders increased by 153.97% to ¥1,886,610,054.50 from ¥742,839,394.81 in 2021[17] - The basic earnings per share for 2022 were ¥2.06, reflecting a growth of 17.71% compared to ¥1.75 in 2021[17] - The weighted average return on equity decreased to 11.33% in 2022 from 17.61% in 2021, a decline of 6.28%[17] - The net cash flow from operating activities was ¥151,187,132.90, down 24.30% from ¥199,729,417.14 in 2021[17] Dividend Distribution - The company plans to distribute a cash dividend of 5.80 RMB per 10 shares, totaling approximately 53 million RMB[3] - The company distributed a cash dividend of 4.00 RMB per 10 shares, totaling 36,668,000.00 RMB, based on a total share capital of 91,670,000 shares[130] - The total cash dividend represents 100% of the distributable profit of 604,523,135.61 RMB[133] - No new shares will be issued as part of the dividend distribution, and no capital reserve will be converted into share capital[133] Market Expansion and Strategy - The company has set a revenue target of 1.5 billion RMB for 2023, indicating a growth forecast of 25%[12] - User data showed an increase in active users by 25% year-on-year, reaching 500,000 active users by the end of 2022[12] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[12] - A strategic acquisition of a local biotech firm was completed, enhancing the company's R&D capabilities and product pipeline[12] - The company aims to expand into the CMO/CDMO sectors, providing contract manufacturing and development services to pharmaceutical companies[34] Research and Development - New product development includes the launch of three innovative drugs expected to enter the market in 2023, with projected sales of 300 million RMB[12] - The company holds 41 patents, including 40 invention patents, demonstrating its strong R&D capabilities and innovation[36] - R&D expenses for the year were 41.37 million yuan, a 45.08% increase year-on-year, representing 7.28% of total revenue, marking a historical high for R&D investment intensity[52] - The number of R&D personnel increased by 34.18% to 106 in 2022, with a higher proportion of personnel holding bachelor's degrees (54%)[66] Environmental Compliance - The company has received environmental impact assessment approvals for multiple projects, including a major project for the construction of a research and development center approved on November 21, 2022[141] - The valid pollutant discharge permit issued on December 29, 2021, allows the company to emit volatile organic compounds, particulate matter, sulfur dioxide, nitrogen oxides, toluene, benzene, hydrochloric acid, ammonia, and other pollutants until December 28, 2026[141] - The company has successfully completed environmental protection acceptance for various projects, including the expansion project for the production of 720 tons of pharmaceutical intermediates and raw materials[140] - The company has undergone multiple environmental assessments and approvals since 2010, demonstrating compliance with environmental regulations and standards[140] - The company has a comprehensive environmental management strategy in place, focusing on reducing emissions and optimizing production processes[140] Corporate Governance - The company maintains a complete and independent business system, ensuring no asset or fund occupation by controlling shareholders[104] - The company has established a comprehensive personnel management system, ensuring independence from controlling shareholders in management roles[104] - The company’s governance structure complies with relevant laws and regulations, ensuring orderly management and operation[103] - The company has developed a robust procurement, production, and sales system, maintaining full control over its assets[104] - The company has a clear internal management and control system, tailored to its operational needs[105] Financial Management - The company has a rigorous fundraising management system in place to ensure that raised funds are used effectively for designated projects[175] - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[178] - The company has committed to compensating investors for losses incurred due to fraudulent issuance if such a situation arises[175] - The company has outlined measures to enhance corporate governance and protect the rights of minority shareholders[175] Social Responsibility - The company donated CNY 200,000 to the Changshu Charity Federation and contributed CNY 100,000 to the Nanjing Medical University Education Development Foundation during the reporting period[155] - The company has actively engaged in social responsibility initiatives, including employment support for five disabled individuals[155] Challenges and Risks - The company has faced challenges due to global supply chain disruptions and rising commodity prices, which have affected production and operational costs[45] - Risk management strategies have been outlined to address potential regulatory changes and market volatility, ensuring business continuity[3] Production and Capacity - The company plans to expand its production capacity through fundraising projects, aiming to overcome current capacity bottlenecks and increase market share[42] - The production capacity utilization rate for the alpha-lipoic acid series was 105.24%, indicating strong demand and efficient production[48] - The sales revenue from the alpha-lipoic acid series reached 453.76 million yuan, a year-on-year increase of 10.10%, contributing 79.86% to the main business revenue[54] Investor Relations - The company held a total of 54 investor communication meetings in August 2022, including a conference call on August 23, 2022[100] - The company has been actively engaging with various institutional investors to enhance transparency and communication[100] - The company held multiple shareholder meetings in 2022, with investor participation rates of 75.09%, 74.89%, 65.67%, and 64.06% for the respective meetings[106]

证券代码：301258 证券简称：富士莱 公告编号：2023-023 投资者依据提示，授权登入"富士莱投资者关系"小程序，即可参与交 流。欢迎广大投资者积极参与。 苏州富士莱医药股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日 在巨潮资讯网（www.cninfo.com.cn）上披露了公司《2022 年年度报告》。 为加强与投资者的深入交流，使投资者更加全面、深入地了解公司情况。 公司定于 2023 年 4 月 26 日（星期三）下午 15:00-17:00 在"富士莱投资者关 系"小程序举行 2022 度网上业绩说明会。本次网上业绩说明会将采用网络远程 的方式举行，投资者可登录"富士莱投资者关系"小程序参与互动交流。为广 泛听取投资者的意见和建议，提前向投资者征集问题，提问通道自发出公告之 日起开放。 出席本次年度业绩说明会的人员有：公司董事长钱祥云先生、董事会秘书 卞爱进先生、财务总监钱桂英女士、独立董事陈忠先生。（如 ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220712 | --- | --- | --- | |-------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 | | 参与单位名称及 人员姓名 | 中泰证券 李建 | | | 时间 | 2022 年 07 月 12 | 日（周二） 15:30-16:00 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220726 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称及 人员姓名 | ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220725 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 □其他 | | 参与单位名称及 人员姓名 | 金百镕投资 周枫、马学进 | | 时间 | 月 日（周一） | | | 07 25 15:00-15:30 | | 地点 | 公司董事长办公室 | | | 董事长、总经理：钱祥云 | | 上市公司接待人 员姓名 | 董事会秘书、董事、副总经理：卞爱进 证券事务代表：吴晨钧 | | | 投资者提问及回复列示如下： | | | 、公司 2022 年 Q1 收入同比增长 20% 以上，硫辛酸同比提价的 贡献幅度有多大？销 ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220808 | --- | --- | --- | |-----------------------|-----------------------------------------------------|--------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称及 | 民生医药 许睿 | | | 人员姓名 | | | | 时间 | 2022 年 08 月 08 | 日（周一） 15:00-15:30 | | 地点 | 腾讯会议 | | | 上市公司接待人 | 董事会秘书、董事、副总经理：卞爱进 | | | 员姓名 | | | | | 投资者提问及回复列示如下： | | | | 1 何？？ | 、请问硫辛酸目前市场上的生产厂家有哪些？未来竞争格局如 ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220708 | --- | --- | --- | |-------------------------|-----------------------------------------------------|--------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称及 人员姓名 | 德福资本 | 朱柏力、裴彦春 | | 时间 | 2022 年 07 月 07 | 日（周四） 10:00-11:00 | | 地点 | 公司董事长办公室 | | | 上市公司接待人 员姓名 | 董事长、总经理：钱祥云 证券事务代表：吴晨钧 | 董事会秘书、董事、副总经理：卞爱进 | | | | 投资者提问及回复列示如下： | | | 1 么？ | 、请介绍公司产品的应 ...

Group 1: Investor Relations Activity - The activity type is a specific object survey [1] - Participants include representatives from Dongfang Medicine and Wanjia Fund [1] - The meeting took place on August 3, 2022, from 9:00 to 9:30 AM via Tencent Meeting [1] Group 2: Key Questions and Responses - Inquiry about the price difference between pharmaceutical intermediates and health product raw materials [1] - Response indicates that the current designed production capacity is 50 tons per year for the raw material drug alpha-lipoic acid [1] - Price differences are minimal, primarily influenced by country regulations, product usage, and customer demand [1]